Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We evaluated the efficacy and safety of azithromycin in hospitalised patients with COVID-19. Methods In this randomised, controlled, open-label, adaptive platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once daily by mouth or intravenously for 10 days or until discharge (or one of the other treatment arms).



Ragesoss CC BY-SA 4.0 (], from Wikimedia Commons

Read more…


Citation: Peter W HorbyAlistair RoddickEnti SpataNatalie StaplinJonathan R EmbersonGuilherme Pessoa-AmorimLeon PetoMark CampbellChristopher BrightlingBen PrudonDavid ChadwickAndrew UstianowskiAbdul AshishStacy ToddBryan YatesRobert ButteryStephen ScottDiego MasedaJ Kenneth BaillieMaya H BuchLucy C ChappellJeremy N DaySaul N FaustThomas JakiKatie JefferyEdmund JuszczakWei Shen LimAlan MontgomeryAndrew MumfordKathryn RowanGuy ThwaitesMarion MafhamRichard HaynesMartin J LandrayRECOVERY Collaborative Group